Data from FDA - Curated by EPG Health - Last updated 31 August 2017

Indication(s)

INDICATIONS Varicose Ulcers Debride Eschar Dehiscent Wounds Decubital Ulcers Sunburn Wound Healing GRANULEX will relieve pain and promote healing; debrides eschar and necrotic tissue physiologically; stimulates vascular bed; improves epithelization by reducing premature epithelial desiccation and cornification; reduces odor from malodorous necrotic wounds.

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Acute and Advanced Heart Failure

Acute and Advanced Heart Failure

What are the most effective treatments for acute heart failure? Can you define advanced heart failure? Discover here...

+ 3 more

Allergic Rhinitis

Allergic Rhinitis

Allergic rhinitis causes great strain on the workforce. Help to reduce sick days and improve productivity with appropriate treatment options.

+ 4 more

Atopic Dermatitis

Atopic Dermatitis

The Atopic Dermatitis Knowledge Centre is an educational resource, intended for healthcare professionals, that provides credible medical information on the epidemiology, pathophysiology and burden of atopic dermatitis, as well as diagnostic techniques, treatment regimens and guideline recommendations.

Load more

Related Content

Journal articles

Use of levosimendan in acute heart failure.

As a calcium sensitizer and inodilator that augments cardiac contractility without increasing myocardial oxygen demand or exacerbating ischaemia, levosimendan may be well configured to deliver inotropic support in cases of acute heart failure (AHF).

Added 4 days ago

Repetitive levosimendan treatment in the management of advanced heart failure.

Inotropes may be an appropriate treatment for patients with advanced heart failure (AdHF) who remain highly symptomatic despite optimized standard therapies.

Added 4 days ago

Teenagers and young adults with nephropathic cystinosis display significant bone disease and cortical impairment.

Background: Bone impairment appears to be a novel complication of nephropathic cystinosis despite cysteamine therapy. Its exact underlying pathophysiology is nevertheless unclear.

Added 5 days ago

Skeletal Consequences of Nephropathic Cystinosis.

Nephropathic cystinosis is a rare lysosomal storage disorder. Patients present in the first year of life with renal Fanconi syndrome that evolves to progressive chronic kidney disease (CKD).

Added 5 days ago

Ocular changes in nephropathic cystinosis: The course of the gold-dust.

In the cornea, crystalline, gold-dust deposition of cystine leads to visual impairment, recurrent erosions, photophobia, epiphora and blepharospasmus.

Added 5 days ago

Load more

View all 12845 Journal articles items
Guidelines

Clinical Practice Guidelines for the Management of Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption in Adult Patients in the ICU (Devlin et al., 2018)

To update and expand the 2013 Clinical Practice Guidelines for the Management of Pain, Agitation, and Delirium in Adult Patients in the ICU.

Added 28 days ago

2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy

2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy

Added 4 months ago

Recurrent pregnancy loss

The overall aim of this guideline is to supply healthcare providers with the best available evidence for investigation and treatment of women with recurrent pregnancy loss.

Added 6 months ago

Recommendations for the Surgical Treatment of Endometriosis. Part 1: Ovarian Endometrioma

This document provides recommendations covering technical aspects of different methods of surgery for endometriomas in women of reproductive age.

Added 6 months ago

International evidence-based guideline for the assessment and management of polycystic ovary syndrome 2018

Objective: To develop and translate rigorous, comprehensive evidence-based diagnosis, assessment and treatment guidelines, to improve the lives of women with polycystic ovary syndrome (PCOS) worldwide.

Added 6 months ago

Load more

View all 1445 Guidelines items

More information

Category Value
Agency product number 8P5F881OCY
Orphan designation No
Product NDC 51079-621
Date Last Revised 27-09-2012
Type HUMAN PRESCRIPTION DRUG
RXCUI 1545801
Marketing authorisation holder Mylan Institutional Inc.